Hybrid molecules based on 1,3,5‐triazine as potential therapeutics: A focused review

Parteek Prasher, Mousmee Sharma, Alaa A. A. Aljabali, Gaurav Gupta, Poonam Negi, Deepak N. Kapoor, Inderbir Singh, Flavia C. Zacconi, Terezinha Jesus Andreoli Pinto, Mateus Webba Da Silva, Hamid A. Bakshi, Dinesh Kumar Chellappan, Murtaza M. Tambuwala, Kamal Dua

Research output: Contribution to journalReview article

Abstract

Majority of the representative drugs customarily interact with multiple targets manifesting unintended side effects. In addition, drug resistance and over expression of the cellular efflux-pumps render certain classes of drugs ineffective. With only a few innovative formulations in development, it is necessary to identify pharmacophores and novel strategies for creating new drugs. The conjugation of dissimilar pharmacophoric moieties to design hybrid molecules with an attractive therapeutic profile is an emerging paradigm in the contemporary drug development regime. The recent decade witnessed the remarkable biological potential of 1,3,5-triazine framework in the development of various chemotherapeutics. The appending of the 1,3,5-triazine nucleus to biologically relevant moieties has delivered exciting results. The present review focuses on 1,3,5-triazine based hybrid molecules in the development of pharmaceuticals.
Original languageEnglish
Pages (from-to)837-858
Number of pages22
JournalDrug Development Research
Volume81
Issue number7
Early online date24 Jun 2020
DOIs
Publication statusPublished - 10 Nov 2020

Keywords

  • 1,3,5-triazine
  • anti-Alzheimer's activity
  • anti-inflammatory activity
  • anticancer activity
  • antimicrobial activity
  • antiplasmodial activity
  • hybrids
  • multidrug-resistance

Fingerprint Dive into the research topics of 'Hybrid molecules based on 1,3,5‐triazine as potential therapeutics: A focused review'. Together they form a unique fingerprint.

Cite this